Our site uses cookies to offer a better navigation functionality, including "third party" cookies and "profiling cookies" designed to send on-line commercial communications in line with the preferences expressed by the user while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here to disable them. Upon proceeding with browsing this website, you will be consenting to the use of cookies.
MEN1112

Humanized de-fucosylated monoclonal antibody against acute myeloid leukemia

Current development phase: phase I

MEN1112 is the first monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics)
MEN 1112 is a humanized de-fucosylated monoclonal IgG1 antibody against a target antigen. This antigen is over expressed in patient blasts who have acute myeloid leukemia. 


Therapeutic Areas

 

Discover all of Menarini's products marketed in Italy.

READ MORE »

Diagnostics

 

Advanced Technology

READ MORE »

The Menarini Group

 

Discover the leading Italian pharmaceutical company in the world.

READ MORE »

Quality first

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »